Members
Margin of Safety Dashboard
Research Notes
My Profile
Logout
Investing
How It Works
Free Research
Stocks We Cover
Writing
Articles
Newsletter
Newsletter
Data
Biotech Company DB
Data Visualizations
About
What Is Solt DB?
Public Benefit
Announcements
Our Lonely Team
Pricing
Login
Newsletter
My Profile
Login
Econ-omics
Why Aren't There Any $1 Trillion Biotech Companies?
July 22, 2024
The world's largest companies, from the Dutch East India Company in the 1640s to Apple in 2024, were driven by globally distributable products. Living technology doesn't have one yet – not even obesity drugs will come close.
BY
Maxx Chatsko
Illumina Created the Blueprint for a Biotech Funding Crunch
Econ-omics
July 11, 2024
Opinion | The Synthetic Biology Ideology
Founder's Blog
May 6, 2024
Ginkgo Bioworks Broke Its Stock. Here's How to "Fix" It
Finance
April 16, 2024
Guardant Health's Next Big Challenge: Reimbursement
Finance
April 1, 2024
World's Bestselling Drugs Addicted to Broken U.S. Healthcare System
Data Dives
March 25, 2024
Is Biology Making Gains in EPA Green Chemistry Challenge?
Data Dives
October 26, 2023
Will Supercomputers and AI Drive Biotech Breakthroughs?
Tech Dives
October 20, 2023
Explore Articles
Explore Articles
Solt DB is a public benefit company.
We're doing things differently.
No
ads, sponsors, or cheerleading
100%
transparent investments
Free
high-quality databases
We teach scientists about investing.
Subscriptions to biotech stock research keep our website 100% ad, sponsor, and clickbait free. We nerd out with free public content, too.
Articles
Data Visualizations
Free Research
Wall Street is Overlooking the Strength of Wakix
June 21, 2025
No matter how investors slice it, Wakix is dominating the commercial landscape in narcolepsy treatments. In fact, it's been responsible for over two-thirds of the overall market's growth since launching in 2019.
By
Maxx Chatsko
Free Research
New LNP Delivers for Verve Therapeutics. Can Eli Lilly Price It?
April 16, 2025
A refined lipid nanoparticle may deliver a base editing payload into liver cells more safely than its predecessor. But the biggest risk might be commercializing it.
By
Maxx Chatsko
Free Research
Krystal Biotech's R&D Austerity Presents Unique Risk
March 24, 2025
Despite solid cash flow from Vyjuvek, the gene therapy developer is neglecting R&D investments. The potential consequences are being ignored by investors and Wall Street.
By
Maxx Chatsko
Free Research
AVITA Medical Needs to Build Durable Momentum in 2025
February 24, 2025
Despite whiffing on revenue guidance for half of 2024, management came out swinging once again. Full-year 2025 revenue guidance calls for record growth of 61%.
By
Maxx Chatsko
Explore Articles
Biopharma
Finance
Annual Revenue of FDA-Approved PCSK9 Inhibitors
April 16, 2025
The ability to block PCSK9 proteins with antibody drugs and genetic medicines is one of the most effective pharmaceutical interventions to lower LDL cholesterol. The three FDA-approved PCSK9 inhibitors combined for $3.7 billion in global revenue during 2024 and $13.7 billion in cumulative lifetime sales.
Read More >
Biopharma
Industry Data
How Many Lab Animals are Used in Drug Development?
April 14, 2025
The types of animals used in preclinical drug development activities vary by therapeutic modality. The largest drug developers purchase tens of thousands of animals for research use each year, primarily mice and other rodents.
Read More >
Biopharma
Finance
Arrowhead Pharma Revenue vs. R&D Cash Expenses, 2018 to 2025
March 14, 2025
A lucrative partnership with Johnson & Johnson in chronic hepatitis B allowed the RNAi pioneer to build a broad pipeline. The latest megadeal with Sarepta Therapeutics continues the monetization trend.
Read More >
Explore More DVs
How do we make money?
Solt DB is a biotech equities research firm. Members have access to written research notes, a real-time margin of safety dashboard, and our real-money portfolio that puts our research into action.
How It Works
Pricing
-cropped.svg)
.svg){kind=small}
.svg)
%20(squoosh).jpg)
.avif)